Archer Daniels Midland Co. (A1DM34) Chart

Play Episode

25min

Proactive - Interviews for investors

Daniel Tillett on Race Oncology’s drug advancements

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection

Proactive - Interviews for investors

BioHarvest Sciences achieves breakthrough in Liver health with Olive Cell compound

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Proactive - Interviews for investors

NSX CEO highlights mining focus & direct listings as key growth drivers for 2025

National Stock Exchange of Australia CEO Max Cunningham talked with Proactive's Angela Harmantas from the PDAC conference in Toronto about the exchange’s role in the Australian market, its focus on mining companies, and its expansion plans. Cunningham explained that the NSX is one of two active stock exchanges in Australia with a tier-one license, allowing it to serve all investors, including retail. He highlighted that around one-third of the exchange’s listings are mining-related, with strong growth potential in the sector. Cunningham noted that NSX is working to fill a gap in the Australian venture market and is focusing on attracting mining companies, especially from regions like Perth. He also emphasized the importance of international relationships, mentioning cross-listing agreements with Canadian exchanges such as the CSE and TSX, as well as OTC Markets. Looking ahead to 2025, Cunningham discussed the challenges of IPOs due to regulatory hurdles and capital-raising difficulties. Instead, the NSX is prioritizing direct listings, which allow companies to go public without raising capital upfront. He stated that NSX is seeing increased interest from firms moving from the incumbent Australian exchange, as well as from Canadian companies seeking dual listings. #NSX #StockMarket #MiningStocks #IPOs #DirectListings #PDAC2025 #Investing #AustralianMarkets #DualListings #CapitalMarkets

Proactive - Interviews for investors

Sprott & HANetf launch physical uranium ETC targeting European investors

Sprott Asset Management CEO John Ciampaglia talked with Proactive's Stephen Gunnion about the launch of the Sprott Physical Uranium ETC (ISE:SPUT) in partnership with HANetf. Ciampaglia explained that this new product is an extension of the Sprott Physical Uranium Trust, a popular investment vehicle that trades on the Toronto Stock Exchange. According to Ciampaglia, the new ETC aims to address a key gap in the market by providing non-institutional European investors with easier access to uranium investment. He noted that uranium plays a crucial role in the global energy transition, as nuclear energy is gaining renewed interest due to its ability to provide baseload power, energy security, and zero greenhouse gas emissions. Ciampaglia also discussed the differences between investing in physical uranium versus uranium mining stocks. He emphasised that physical uranium is often considered a cornerstone investment, while uranium miners offer greater upside potential and operating leverage. Many investors, he said, choose to balance both approaches in their portfolios. Watch the full interview for more insights into uranium investing and the future of nuclear energy. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for updates. #Sprott #Uranium #NuclearEnergy #Investing #HANetf #EnergySecurity #ETC #MiningStocks #PhysicalUranium #ProactiveInvestors

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover